

wherein each occurrence of M is independently CV_2, -NV-, -O- or -S-, wherein each occurrence of V is independently hydrogen, OH, halogen, or aliphatic; each occurrence of Y is independently a covalent bond, -O-, -S- or $N(R_J)_2$, wherein R_J, for each occurrence, is independently hydrogen, aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl; each occurrence of x is independently 1 or 2; and each occurrence of R_1 is independently hydrogen, aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, alkylheteroaryl, a prodrug or pharmaceutically acceptable derivative.

b) Please replace claim 113 with the following amended claim 113:

113. The compound of claim 108 or 112, wherein R_C is $-ZR_E$, wherein Z is -O-, -S-, or NR_F, wherein R_E is hydrogen, or an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, and R_F is an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, whereby at least one of R_E or R_F represents a cyclic or acyclic aliphatic or heteroaliphatic moiety, whereby at least one of said cyclic or acyclic aliphatic or heteroaliphatic moieties is substituted by at least one phosphorus moiety.

Marked-Up Copies of Claims 108 and 113:

108. The compound of claim 1, wherein R_C [is defined as above] is cyclic or acyclic aliphatic or heteroaliphatic, or $-ZR_E$, wherein Z is -O-, -S-, or NR_F, wherein R_E is hydrogen, or an aliphatic, heteroaliphatic, aryl, heteroaryl, alkylaryl, or alkylheteroaryl moiety, and R_F is an aliphatic,